Engineered phosphopentomutase variant enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for more effective compounds that inhibit HIV reverse transcriptase to ameliorate the effects of AIDS, as existing nucleoside analogues like MK-8591 face challenges in production due to their chemical complexity.
Innovation Solution
Engineered phosphopentomutase (PPM) enzymes with specific polypeptide sequences and substitutions are developed to enhance the production of pharmaceutical compounds targeting HIV reverse transcriptase inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If nucleoside analogues are produced by standard chemical synthetic techniques, then the compounds can be manufactured, but the production process becomes complex and challenging due to chemical complexity
Solution Approach 1:
The patent changes the production approach from chemical synthesis to enzymatic synthesis, fundamentally altering the parameters of the manufacturing process. This involves using engineered phosphopentomutase enzymes to catalyze the conversion of ribonucleosides to deoxynucleosides, thereby simplifying the production process while maintaining the ability to manufacture complex nucleoside analogue compounds
Solution Approach 2:
The patent replaces chemical synthesis mechanisms with enzymatic mechanisms. Instead of using complex chemical reagents and multi-step chemical reactions, the invention employs engineered enzymes (phosphopentomutases) to catalyze the desired chemical transformations, thereby reducing production complexity and improving ease of manufacture
2Reliability
If more effective reverse transcriptase inhibitors are developed, then the treatment efficacy for AIDS is improved, but the production complexity increases
Solution Approach 1:
The patent changes the production parameters by introducing engineered enzymes with specific amino acid substitutions that enhance catalytic efficiency. This allows for the production of more effective nucleoside analogue inhibitors through a simplified enzymatic process rather than complex chemical synthesis
Solution Approach 2:
The patent introduces engineered phosphopentomutase enzymes as intermediaries in the production process. These enzymes serve as biocatalysts that simplify the conversion of substrates to active pharmaceutical ingredients, thereby enabling the production of effective inhibitors without proportionally increasing production complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered PPM enzymes provide enhanced inhibition of HIV reverse transcriptase, offering a more effective approach to treating AIDS by improving the production of nucleoside analogues.
Implementation Method 1
engineered phosphopentomutase (PPM) enzymes with specific polypeptide sequences and substitutions are developed to enhance the production of pharmaceutical compounds targeting HIV reverse transcriptase inhibition
Data Source
AI summary
The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.